Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues
Royalty and licensing revenue	$ 4,185	$ 0	$ 8,887	$ 3,750
Treatment investment revenue	63	22	170	54
Grant revenue	118	0	163	0
Total revenue	4,366	22	9,220	3,804
Operating expenses
General and administrative	3,398	2,175	9,220	6,295
Research and development	1,908	691	5,945	2,963
License fees	0	0	5,625	0
Total operating expenses	5,306	2,866	20,790	9,258
Loss from operations	(940)	(2,844)	(11,570)	(5,454)
Other income (expense)
Interest income, net	20	7	31	29
Loss on settlement of liability	0	(33)	(50)	(33)
Gain (Loss) on foreign exchange	2	11	(36)	41
Total other income (expense)	22	(15)	(55)	37
Loss before provision for income taxes	(918)	(2,859)	(11,625)	(5,417)
Provision for income taxes	0	550	33	550
Net loss	$ (918)	$ (3,409)	$ (11,658)	$ (5,967)
Net loss per share of common stock:
Basic and Diluted (in dollars per share)	$ (0.32)	$ (1.68)	$ (4.32)	$ (2.96)
Weighted average shares outstanding used to compute net loss per share:
Basic and Diluted (in shares)	2,871,042	2,026,477	2,698,532	2,018,986